Patent ID: 9732133
Date: 2017-08-15
CPC Classifications: A61K,C07K

Claim:
1. A modified IL-13 antagonist polypeptide engineered to have (a) decreased affinity for interleukin 13 receptor α2 (IL-13Rα2), relative to native human IL 13 protein; (b) and increased affinity for interleukin 13 receptor α1 (IL-13Rα1) relative to native human IL-13 protein, wherein the modified IL-13 polypeptide comprises amino acid changes relative to wild type IL-13 at positions V18, D87, T88, L101, K104, and K105; and comprising amino acid substitutions E12A/G/S and R65D/E, wherein the polypeptide is conjugated or fused to a therapeutic or labeling moiety.